The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells

Oncogene

Volumn 31, Issue 16, 2012, Pages 2049-2061

  Duran Prado M ^a   Gahete, M D ^a   Hergueta Redondo, M ^b,c   Martinez Fuentes A J ^a   Cordoba Chacon J ^a   Palacios, J ^d   Gracia Navarro, F ^a   Moreno Bueno, G ^b,c   Malagon M M ^a   Luque, R M ^a   Castao J P ^a  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

breast cancer; poor prognosis; somatostatin receptors; sst2; sst5TMD4

Indexed keywords

ACTIN RELATED PROTEIN 2-3 COMPLEX; CYCLIN D3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SOMATOSTATIN RECEPTOR; SST5TMD4 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELL STRAIN MCF 7; CLINICAL ARTICLE; CONTROLLED STUDY; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; MESENCHYME; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENETIC VARIATION; HUMANS; MAP KINASE KINASE 1; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROGNOSIS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

MUS MUSCULUS;

EID: 84859921027     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.389     Document Type: Article

References (41)

1. Ben-Shlomo A, Melmed S. (2010). Pituitary somatostatin receptor signaling. Trends Endocrinol Metab 21: 123-133.
2. Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A et al. (2000). Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Nat Acad Sci USA 97: 9180-9185. (Pubitemid 30626694)
3. Cordoba-Chacon J, Gahete MD, Duran-Prado M, Pozo-Salas AI, Malagon MM, Gracia-Navarro F et al. (2010). Identification and characterization of new functional truncated variants of somatostatin receptor subtype 5 in rodents. Cell Mol Life Sci 67: 1147-1163.
4. Charland S, Boucher MJ, Houde M, Rivard N. (2001). Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 142: 121-128. (Pubitemid 32183673)
5. Donovan JC, Milic A, Slingerland JM. (2001). Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 276: 40888-40895.
6. Duran-Prado M, Bucharles C, Gonzalez BJ, Vazquez-Martinez R, Martinez-Fuentes AJ, Garcia-Navarro S et al. (2007). Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization. Endocrinology 148: 411-421. (Pubitemid 46021473)
7. Duran-Prado M, Gahete MD, Martinez-Fuentes AJ, Luque RM, Quintero A, Webb SM et al. (2009). Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 94: 2634-2643.
8. Durán-Prado M, Saveanu A, Luque RM, Gahete MD, Gracia-Navarro F, Jaquet P et al. (2010). A potential inhibitory role for the new truncated variant of somatostatin receptor 5 (sst5TMD4) in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab 95: 2497-2502.
9. Eralp Y, Derin D, Ozluk Y, Yavuz E, Guney N, Saip P et al. (2008). MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol 19: 669-674. (Pubitemid 351461036)
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
11. He Y, Yuan XM, Lei P, Wu S, Xing W, Lan XL et al. (2009). The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells. Acta Pharmacol Sin 30: 1053-1059.
12. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D et al. (2006). Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 155: 371-379. (Pubitemid 44269455)
13. Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
14. Kahan Z, Nagy A, Schally AV, Hebert F, Sun B, Groot K et al. (1999). Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. Int J Cancer 82: 592-598. (Pubitemid 29343462)
15. Keri G, Erchegyi J, Horvath A, Mezo I, Idei M, Vantus T et al. (1996). A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Nat Acad Sci USA 93: 12513-12518. (Pubitemid 26367175)
16. Lee JF, Ozaki H, Zhan X, Wang E, Hla T, Lee MJ. (2006). Sphingosine-1-phosphate signaling regulates lamellipodia localization of cortactin complexes in endothelial cells. Histochem Cell Biol 126: 297-304.
17. Leu FP, Nandi M, Niu C. (2008). The effect of transforming growth factor beta on human neuroendocrine tumor BON cell proliferation and differentiation is mediated through somatostatin signaling. Mol Cancer Res 6: 1029-1042.
18. Liu W, Bagaitkar J, Watabe K. (2007). Roles of AKT signal in breast cancer. Front Biosci 12: 4011-4019.
19. Moller LN, Stidsen CE, Hartmann B, Holst JJ. (2003). Somatostatin receptors. Biochim Biophys Acta 1616: 1-84. (Pubitemid 37272115)
20. Moreno-Bueno G, Salvador F, Martin A, Floristan A, Cuevas EP, Santos V et al. (2011). Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol Med 3: 528-544.
21. Nakanishi O, Suetsugu S, Yamazaki D, Takenawa T. (2007). Effect of WAVE2 phosphorylation on activation of the Arp2/3 complex. J Biochem 141: 319-325. (Pubitemid 46770384)
22. Orlando C, Raggi CC, Bianchi S, Distante V, Simi L, Vezzosi V et al. (2004). Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue. Endocr Relat Cancer 11: 323-332. (Pubitemid 38832833)
23. Perez-Tenorio G, Stal O. (2002). Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86: 540-545. (Pubitemid 34185089)
24. Pola S, Cattaneo MG, Vicentini LM. (2003). Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity. J Biol Chem 278: 40601-40606. (Pubitemid 37280872)
25. Prevost G, Provost P, Salle V, Lanson M, Thomas F. (1993). A crosslinking assay allows the detection of receptors for the somatostatin analogue, lanreotide in human breast tumours. Eur J Cancer 29A: 1589-1592. (Pubitemid 23251803)
26. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M et al. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27: 4656-4663.
27. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K et al. (1999). Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286: 1738-1741. (Pubitemid 129515881)
28. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH et al. (2002). The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80: 239-256. (Pubitemid 34233743)
29. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. (2008). Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68: 989-997. (Pubitemid 351272216)
30. Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H et al. (2005). Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. Mol Cancer 4: 37.
31. Schulz S, Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S et al. (1998). Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 4: 2047-2052. (Pubitemid 28415646)
32. Setyono-Han B, Henkelman MS, Foekens JA, Klijn GM. (1987). Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 47: 1566-1570. (Pubitemid 17044484)
33. Sun LC, Luo J, Mackey LV, Fuselier JA, Coy DH. (2007). A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Lett 246: 157-166. (Pubitemid 44959389)
34. Umemura S, Yoshida S, Ohta Y, Naito K, Osamura RY, Tokuda Y. (2007). Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci 98: 1889-1892. (Pubitemid 350002194)
35. van Eijck CH, Krenning EP, Bootsma A, Oei HY, van Pel R, Lindemans J et al. (1994). Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343: 640-643. (Pubitemid 24087809)
36. Vivanco I, Sawyers CL. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501. (Pubitemid 37328931)
37. Wang W, Goswami S, Sahai E, Wyckoff JB, Segall JE, Condeelis JS. (2005). Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol 15: 138-145. (Pubitemid 40332536)
38. Watt HL, Kharmate G, Kumar U. (2008). Biology of somatostatin in breast cancer. Mol Cell Endocrinol 286: 251-261. (Pubitemid 351680241)
39. Xu Y, Song J, Berelowitz M, Bruno JF. (1996). Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology 137: 5634-5640. (Pubitemid 26423134)
40. Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, Coniglio S, Symons M et al. (2005). Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol 168: 441-452. (Pubitemid 40205066)
41. Zimmermann S, Moelling K. (1999). Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286: 1741-1744. (Pubitemid 129515882)